Clinical evaluation of three tumor markers in hepatocellular carcinoma diagnosis:alpha-fetoprotein-L3, des-gamma-carboxy prothrombin and alpha-fetoprotein

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000032110

Enrollment

Unknown

Registered

2020-04-20

Start date

2020-06-01

Completion date

Unknown

Last updated

2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

des-gamma-carboxy prothrombin and alpha-fetoprotein

Interventions

Gold Standard:Pathology

Index test:HSP70 AFP-L3 GPC3

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) HCC diagnosis and treatment in accordance with the 2011"standard for diagnosis and treatment of Primary Liver Cancer" ; (2) Imaging examination or liver biopsy for the first time confirmed the diagnosis of Liver space-occupying Lesions; (3) A clear history of HBV infection; (4) Liver function classification, Child-pugh Grade A or grade B; (5) Anti-HCV negative.

Exclusion criteria

Exclusion criteria: (1) Metastatic Carcinoma of the liver; (2) Systemic metastasis of hepatocellular carcinoma and / or presence of Cachexia; (3) Benign space-occupying Lesions of the liver; (4) Without HBV-associated HCC; (5) Received surgery, tumor-related drugs and other treatment before admission; (6) Incomplete clinical case data.

Design outcomes

Primary

Measure	Time frame
HSP70 AFP-L3 GPC3;GPC3;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactYang Liping

Gansu Provincial Hospital of Traditional Chinese Medicine

93689078@qq.com+86 18919931860

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026